New pathways for evaluating potential acute stroke therapies

International Journal of Stroke

Volumn 1, Issue 2, 2006, Pages 52-58

  Fisher, Marc ^a,e   Cheung, Kenneth ^b   Howard, George ^c   Warach, Steven ^d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Columbia University Mailman School of Public Health ^*  (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e University of Massachusetts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRINOLYTIC AGENT; NEUROPROTECTIVE AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIFFUSION WEIGHTED IMAGING; DOSE CALCULATION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG LEGISLATION; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAXIMUM TOLERATED DOSE; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

HUMANS; ORGANIZATIONS; POLITICS; STROKE; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 33646154008     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2006.00025.x     Document Type: Review

References (42)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
2. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1: 36-45.
3. Fisher M, Schabitz WR: An overvPew of acute stroke therapy: past, present and future. Arch Int Med 2000; 160: 3196-20.
4. Furlan A, Higashida R, Wechsler LA et al. Intraarterial prourokinase for acute ischemic stroke. The PROACT-2 Study: A randomized controlled trial. JAMA 1999; 282: 2003-11.
5. Sherman DG, Atkinson RP, Chippendale T et al. Intravenous ancrod for treatment of acute ischemic stroke. JAMA 2000; 283: 2395-403.
6. Kidwell CS, Liebeskind DS, Starkman S et al. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001; 32: 1349-5.
7. Fisher M for the Stroke Therapy Academic Industry Roundtable: Recommendations for advancing development of acute stroke therapies. Stroke 2003; 34: 1539-46.
8. Optimising Analysis of Stroke Trials (OAST) Collaborators, Bath PMW: Optimising the statistical analysis of functional outcome in stroke trials. Stroke 2003; 34: 316.
9. Fisher M, Ratan R: New perspectives on developing acute stroke therapy. Ann Neurol 2003; 53: 10-20.
10. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Study Group: Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke 2000; 31: 2912-9.
11. Stroke Therapy Academic Industry Roundtable: Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-8.
12. Marshall JWB, Cummings RM, Bowes LJ et al. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke 2003; 34: 2228-33.
13. Stroke Therapy Academic Industry Roundtable: Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001; 32: 1598-606.
14. Adams H for the AbESTT-II Investigators: Abciximab in emergent stroke treatment trial -II. Presented at the 28th International Stroke Conference (February 2004). Stroke 2004; 34: 252.
15. Miller DH: Biomarkers and surrogate outcomes in neurodegenerative disease: Lessons from multiple sclerosis. NeuroRx 2004; 1: 284-9.
16. Katz R: Evidentiary standards for drug development and approval. NeuroRx 2004; 1: 307-16.
17. Food and Drug Adminstration Modernization Act of 1997, Pub L No. 105-115, 111 Stat 2295, 1997.
18. Peck CA Rubin DB, Sheiner LB: Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval. Clin Pharmacol Ther 2003; 73: 481-90.
19. Katz R: Biomarkers and surrogaAe endpoints: an FDA perspective. NeuroRx 2004; 1: 189-95.
20. MayeuxPR: Biomarkers: potential uses and limitations. NeuroRx 2004; 1: 182-8.
21. Warach S, Pettigrew LC, Dashe JF et al. Effects of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging: Citicoline 010 investigators. Ann Neurol 2000; 48: 713-22.
22. Beaulieu C, Moseley ME: Diffusion-weighted and perfusion-weighted magnetic resonance imaging in clinical stroke in current review of cerebrovascular disease; in Fisher M, Bogousslavsky J (eds): Current Medicine, 4th edn. Philadelphia, 2001: 59-68.
23. Kidwell CS, Saver JL, Mattiello J et al. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000; 47: 462-9.
24. Schellinger PD, Fieback JB, Jansen O et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol 2001; 49: 460-9.
25. Schlaug G, Benfield A, Baird AE et al. The ischemic penumbra: operationally defined by diffusion perfusion MRI. Neurology 1999; 53: 1528-37.
26. Parsons MW, Barber PA, Chalk J et al. Diffusion and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51: 28-37.
27. Neumann-Haeflin T, de Rochemont M, Fiebach JB et al. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle artery occlusion. Stroke 2004; 35: 109-15.
28. Kidwell CS,EAlger JR, Saver JL: Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003; 34: 2729-35.
29. Wintermark M, Bogousslavsky J, Thiren JP et al. Prognostic accuracy of admission cerebral blood flow measurements by perfusion CT in acute stroke patients. Ann Neurol 2002; 51: 417-32.
30. Storer B, DeMets D: CuArent phase I/II designs: are they adequate? Journal Clin Res Drug Dev 1987; 1: 121-30.
31. O'Quigley J, Pepe M, FishAr L: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33-48.
32. Cheung YK, Chappell R: Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000; 56: 1177-82.
33. Cheung YK: On the use of nonparametric curves in phase I trials with low toxicity tolerance. Biometrics 2002; 58: 237-40.
34. Cheung YK, Chappell R: A simple technique to evaluate model sensitivity in the continual reassessment method. Biometrics 2002; 58: 671-4.
35. Zelen M: Play the winner rule and the controlled clinical trials. J Am Statist Assoc 1969; 64: 131-46.
36. Wei LJ, Durham S: The randomized play-the-winner rule in medical trials. J Am Statist Assoc 1978; 73: 840-3.
37. Rosenberger WF, Lachin JM: The use of response-adaptive designs in clinical trials. Controlled Clin Trials 1993; 14: 471-84.
38. Cheung YK, Thall PF: Monitoring the rates of composite events with censored data in phase II clinical trials. Biometrics 2002; 58: 89-97.
39. Pocock SJ: Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-9.
40. Thall PF, Simon R, Ellenberg SS: Two-stage selection and testing designs for comparative clinical trials. Biometrika 1988; 75: 303-10.
41. Diamond GA, KBul S: Prior convictions: bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Col Cardiol 2004; 43: 1929-3.
42. Howard G, Cutter CR, Coffey CS: Is bayesian analysis ready for use in phase III randomized clinical trials? "Beware the Sound of the Sirens". Stroke.